BCL2 and B-cell chronic lymphocytic leukemia: Of note, with the use of venetoclax comes the risk of developing acquired mutations and, therefore, resistance to the treatment, as has previously been shown in CLL (mutations in the BCL-2 family such as BCL2 or BAX, as well as mutations involving BRAF, CDKN2A/B, BTG1).